MY182781A - Stabilized desmopressin - Google Patents

Stabilized desmopressin

Info

Publication number
MY182781A
MY182781A MYPI2016704613A MYPI2016704613A MY182781A MY 182781 A MY182781 A MY 182781A MY PI2016704613 A MYPI2016704613 A MY PI2016704613A MY PI2016704613 A MYPI2016704613 A MY PI2016704613A MY 182781 A MY182781 A MY 182781A
Authority
MY
Malaysia
Prior art keywords
desmopressin
acceptable salt
active ingredient
stabilizing agent
orally disintegrating
Prior art date
Application number
MYPI2016704613A
Other languages
English (en)
Inventor
Bong Sang Lee
Su-Jun Park
Jiyeong Han
Myeongcheol Kil
Min Seop Kim
Hong Ryeol Jeon
Dow Kwon
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53510836&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MY182781(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ferring Bv filed Critical Ferring Bv
Publication of MY182781A publication Critical patent/MY182781A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Inorganic Chemistry (AREA)
  • Physiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MYPI2016704613A 2014-06-16 2015-06-15 Stabilized desmopressin MY182781A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020140073067A KR20150144209A (ko) 2014-06-16 2014-06-16 안정화된 데스모프레신 또는 이의 약학적으로 허용가능한 염을 함유 약학 조성물
PCT/EP2015/063347 WO2015193246A1 (en) 2014-06-16 2015-06-15 Stabilized desmopressin

Publications (1)

Publication Number Publication Date
MY182781A true MY182781A (en) 2021-02-05

Family

ID=53510836

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2016704613A MY182781A (en) 2014-06-16 2015-06-15 Stabilized desmopressin

Country Status (33)

Country Link
US (1) US20170128521A1 (enExample)
EP (1) EP3154516B1 (enExample)
JP (1) JP6615130B2 (enExample)
KR (2) KR20150144209A (enExample)
CN (1) CN106456706B (enExample)
AR (1) AR100850A1 (enExample)
AU (1) AU2015276247C1 (enExample)
CA (1) CA2951768C (enExample)
CL (1) CL2016003219A1 (enExample)
CO (1) CO2017000354A2 (enExample)
DK (1) DK3154516T3 (enExample)
EA (1) EA032834B1 (enExample)
ES (1) ES2751600T3 (enExample)
HR (1) HRP20191746T1 (enExample)
HU (1) HUE045395T2 (enExample)
IL (1) IL249538A0 (enExample)
JO (1) JO3500B1 (enExample)
LT (1) LT3154516T (enExample)
MX (1) MX374540B (enExample)
MY (1) MY182781A (enExample)
NZ (1) NZ727388A (enExample)
PH (1) PH12016502527A1 (enExample)
PL (1) PL3154516T3 (enExample)
PT (1) PT3154516T (enExample)
RS (1) RS59449B1 (enExample)
SA (1) SA516380492B1 (enExample)
SG (2) SG11201609374YA (enExample)
SI (1) SI3154516T1 (enExample)
TN (1) TN2016000561A1 (enExample)
TW (1) TWI670070B (enExample)
UA (1) UA119776C2 (enExample)
WO (1) WO2015193246A1 (enExample)
ZA (1) ZA201608020B (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114432424B (zh) * 2021-12-27 2023-06-27 南通联亚药业股份有限公司 一种稳定的铝塑包装去氨加压素片剂

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE60941B1 (en) * 1986-07-10 1994-09-07 Elan Transdermal Ltd Transdermal drug delivery device
GB0210397D0 (en) * 2002-05-07 2002-06-12 Ferring Bv Pharmaceutical formulations
AU2003233118B8 (en) * 2002-05-07 2009-07-30 Ferring Bv Desmopressin in an orodispersible dosage form
WO2007083323A2 (en) * 2006-01-23 2007-07-26 Panacea Biotec Limited. Modified release oral dosage form comprising desmopressin
CN100463674C (zh) * 2006-12-22 2009-02-25 江苏奥赛康药业有限公司 一种氯雷他定口腔速溶膜及其制备方法
TW201422254A (zh) * 2012-11-21 2014-06-16 Ferring Bv 用於速釋及延釋的組成物
US20150306170A1 (en) * 2012-11-21 2015-10-29 Ferring B.V. Composition for immediate and extended release

Also Published As

Publication number Publication date
TW201605464A (zh) 2016-02-16
ES2751600T3 (es) 2020-04-01
BR112016029417A8 (pt) 2021-06-29
DK3154516T3 (da) 2019-09-23
CA2951768C (en) 2022-08-30
AU2015276247B2 (en) 2019-09-12
AR100850A1 (es) 2016-11-02
AU2015276247A1 (en) 2017-02-02
IL249538A0 (en) 2017-02-28
US20170128521A1 (en) 2017-05-11
HUE045395T2 (hu) 2019-12-30
EP3154516B1 (en) 2019-09-04
UA119776C2 (uk) 2019-08-12
CA2951768A1 (en) 2015-12-23
SI3154516T1 (sl) 2019-11-29
JP6615130B2 (ja) 2019-12-04
CN106456706A (zh) 2017-02-22
EA032834B1 (ru) 2019-07-31
LT3154516T (lt) 2019-10-25
PL3154516T3 (pl) 2020-08-10
RS59449B1 (sr) 2019-11-29
CN106456706B (zh) 2020-07-14
PH12016502527B1 (en) 2017-04-10
KR20170020450A (ko) 2017-02-22
BR112016029417A2 (pt) 2017-08-22
SA516380492B1 (ar) 2021-02-03
TWI670070B (zh) 2019-09-01
EA201692556A1 (ru) 2017-04-28
HRP20191746T1 (hr) 2019-12-27
EP3154516A1 (en) 2017-04-19
NZ727388A (en) 2021-07-30
MX374540B (es) 2025-03-06
TN2016000561A1 (en) 2018-04-04
JP2017523955A (ja) 2017-08-24
CL2016003219A1 (es) 2017-06-30
SG11201609374YA (en) 2017-01-27
WO2015193246A1 (en) 2015-12-23
JO3500B1 (ar) 2020-07-05
MX2016016635A (es) 2017-06-06
KR102360656B1 (ko) 2022-02-09
KR20150144209A (ko) 2015-12-24
ZA201608020B (en) 2020-05-27
PH12016502527A1 (en) 2017-04-10
CO2017000354A2 (es) 2017-03-31
AU2015276247C1 (en) 2020-02-06
SG10201811139UA (en) 2019-01-30
PT3154516T (pt) 2019-12-05

Similar Documents

Publication Publication Date Title
MX2016016593A (es) Nuevos derivados de aminoalquibenzotiazepina y usos de los mismos.
MY187047A (en) Selective pyy compounds and uses thereof
NZ762034A (en) Human plasma kallikrein inhibitors
NZ721298A (en) Pharmaceutical compositions comprising azd9291
PH12017502376B1 (en) Oral solid formulation containing irinotecan and method of preparing the same
MX2016011105A (es) Inhibidores de monoacilglicerol aciltransferasa 2 (mgat2) de dihidropiridinona para usarse en el tratamiento de trastornos metabolicos.
EA201691741A1 (ru) Фармацевтическая композиция
MX2016001422A (es) Composicion farmaceutica de fingolimod.
WO2015001541A3 (en) Pharmaceutical film composition
UA118474C2 (uk) (s)-пірліндол та його фармацевтично прийнятні солі для застосування в медицині
WO2016006974A3 (en) Novel triazolopyrimidinone or triazolopyridinone derivatives, and use thereof
WO2016006975A3 (en) Novel imidazotriazinone or imidazopyrazinone derivatives, and use thereof
EA201890896A1 (ru) Твердый препарат для перорального применения, содержащий аморфный солифенацин, и способ его получения
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
MX385513B (es) Composiciones farmaceuticas que comprenden safinamida.
IN2014MU00859A (enExample)
PH12016502527A1 (en) Stabilized desmopressin
EA201891848A1 (ru) Фармацевтическая композиция для применения в лечении фиброза
IN2014MU01179A (enExample)
IL259083A (en) Pharmaceutical composition containing, as active ingredient, 7-azaindolin-2-one derivative or pharmaceutically acceptable salt thereof
AU2017900496A0 (en) Compounds for Enhancing the Permeation of Active Pharmaceutical Ingredients through Skin
MX2018007272A (es) Composicion farmaceutica de liberacion pulsatil que comprende naftazona o una de sus sales.
IN2014MU01178A (enExample)
IN2015MU00907A (enExample)
MX2014008984A (es) Proceso de obtencion y composicion farmaceutica de fenofibrato capsulas como agente regulador de lipidos para su administracion oral.